New Assay Expands INDIGO’s GPCR Portfolio and Supports Development of Next-Generation CNS-Related Therapeutics STATE ...

A multinational research team led by researchers at Institute of Science Tokyo, RIKEN, and the University of Toronto has revealed how a tryptophan-rich allosteric communication network regulates ...

T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on exquisitely timed molecular signals. Now researchers have captured one of the ...

For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 ...

A cluster of recent studies has sharpened the scientific picture of how T cells switch on, tracking the molecular signals ...

The findings of this cohort study suggest that glucagon-like peptide–1 receptor agonist (GLP-1 RA) use was associated with significant reduction in all-cause mortality among patients with cancer with ...

Scientists have discovered that T cell receptors activate through a hidden spring-like motion that had never been seen before. This breakthrough may help explain why immunotherapy works for some ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that it has selected ASC39, a potent and amylin-selective oral small molecule amylin receptor agonist, as a clinical development candidate.

When it comes to brain proteins, small changes can make a dramatic difference. Researchers studying NMDA (N-methyl-D-aspartate) receptors, which are essential for learning, memory and moment-by-moment ...

The dominant paradigm of metabolic treatment has long operated within a narrow frame: reduce caloric intake, increase caloric expenditure, manage the consequences. That framework is now obsolete. The ...